Business
PURE Bioscience Reports Fiscal Second Quarter 2025 Financial Results
EL CAJON, Calif., March 17, 2025--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter ended January 31, 2025.
About this update from Pure Bioscience
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":4008,"height":1391,"url":"https://media.zenfs.com/en/business-wire.com/c63611e6b162378707695e499e4a465f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nWI.B0HaP7kNY5SUxBQ74g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMzMztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c63611e6b162378707695e499e4a465f","width":960,"height":333},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/YjhxeUa395_fFRISuLFaaQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MzI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/c63611e6b162378707695e499e4a465f","width":1200,"height":416}},"lazy":false},{"type":"text","content":"EL CAJON, Calif., March 17, 2025--(BUSINESS WIRE)--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal second quarter ended January 31, 2025.","length":317,"tagName":"p"},{"type":"text","content":"Summary of Results – Fiscal Second Quarter Operations","length":53,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net product sales were $391,000 and $325,000 for the fiscal second quarter ended January 31, 2025 and 2024, respectively. The increase of $66,000 was attributable to increased sales across our distribution network.","length":214,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Net loss for the fiscal second quarter ended January 31, 2025, was $798,000, compared to $1,002,000 for the fiscal second quarter ended January 31, 2024. Selling, general, and administrative expenses decreased by $194,000. The decrease was due to reductions in personnel costs, professional service fees, and share-based compensation.","length":334,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Net loss, excluding share-based compensation, for the fiscal second quarter ended January 31, 2025, was $771,000, compared to $938,000 for the fiscal second quarter ended January 31, 2024.","length":188,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Net loss per share was ($0.01) for the fiscal second quarters ended January 31, 2025 and 2024, respectively.","length":108,"tagName":"p","a...